Travere (TVTX) FDA Approves FILSPARI for Rare Kidney Disease

AI Summary

Travere Therapeutics Inc. (NASDAQ:TVTX) received FDA approval on April 13 for FILSPARI (sparsentan), making it the first medication approved to treat focal segmental glomerulosclerosis (FSGS). The approval is backed by data from the Phase 3 DUPLEX Study, which showed a 48% reduction in proteinuria for treated patients after 108 weeks, compared to 27% for the comparator drug. This approval expands TVTX's market potential to over 100,000 patients in the U.S. with FSGS, alongside its existing indication for IgA nephropathy. This positions Travere to grow in the rare kidney disease sector, which could positively impact its market valuation.